Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 31, 2024

Concordance Between CA-125 and Radiologic Progression Is Poor in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on PARP Inhibitor Maintenance

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor
J. Clin. Oncol 2024 Jan 12;[EPub Ahead of Print], A Tjokrowidjaja, ML Friedlander, JA Ledermann, RL Coleman, MR Mirza, UA Matulonis, E Pujade-Lauraine, SJ Lord, CL Scott, S Goble, W York, CK Lee

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading